Company intelligence / Profile preview

Aethlon Medical, Inc.

San Diego, California, United Statesaethlonmedical.com ↗

Ownership: Public · AEMD
Development stage: Other

Overview

Currently conducting Phase 1 safety, feasibility, and dose-finding clinical trials of the Hemopurifier in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment in Australia and India. The first patient was enrolled in the Australian trial in November 2024. The company has also published preclinical data on the Hemopurifier in the Transplant Immunology journal in March 2025, suggesting expanded therapeutic potential beyond virology and oncology.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Medical DeviceImmunotherapeutic Device
Industry: Therapeutic Medical Devices

Financials

Market cap: $2.8M
Total revenue: $0
Enterprise value: $-1.8M

Beyond the preview

Go deeper on Aethlon Medical, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aethlon Medical, Inc..